[Retracted] Integrative Nomogram of Computed Tomography Radiomics, Clinical, and Tumor Immune Features for Analysis of Disease-Free Survival of NSCLC Patients with Surgery
Table 1
Patient demographics in the study.
Characteristic
All
Survival group
Death group
P value
No. of patients
146
90 (61.6%)
56 (38.4%)
Age
60.24 ± 8.637
59.733 ± 8.751
61.054 ± 8.465
0.371a
Sex
0.076b
Male
83 (56.8%)
46 (51.1%)
37 (66.1%)
Female
63 (43.2%)
44 (48.9%)
19 (33.9%)
Family history of cancer
35 (24.0%)
23 (25.6%)
12 (21.4%)
0.0057b
Smoking quantity (cigarette)
0.007∗d
<1w
72 (49.3%)
50 (55.6%)
22 (39.3%)
1w–20w
18 (12.3%)
9 (10.0%)
9 (16.1%)
20w–50w
48 (32.9%)
24 (26.7%)
24 (42.9%)
>50w
8 (5.5%)
7 (7.8%)
1 (1.8%)
Tumor immune contexture
PD-L1
0.418d
−
106 (72.6%)
69 (76.7%)
37 (66.1%)
+
16 (11.0%)
9 (10.0%)
7 (12.5%)
++
15 (10.3%)
8 (8.9%)
7 (12.5%)
+++
9 (6.2%)
4 (4.4%)
5 (8.9%)
CD8
0.346d
−
84 (57.5%)
51 (56.7%)
33 (58.9%)
+
43 (29.5%)
29 (32.2%)
14 (25.0%)
++
18 (12.3%)
9 (10.0%)
9 (16.1%)
+++
1 (0.7%)
1 (1.1%)
0 (0.0%)
CD3
0.734d
−
21 (14.4%)
15 (16.7%)
6 (10.7%)
+
27 (18.5%)
16 (17.8%)
11 (19.6%)
++
67 (45.9%)
41 (45.6%)
26 (46.4%)
+++
31 (21.2%)
18 (20.0%)
13 (23.2%)
CD4
0.440d
−
58 (39.7%)
36 (40.0%)
22 (39.3%)
+
39 (26.7%)
21 (23.3%)
18 (32.1%)
++
45 (30.8%)
31 (34.4%)
14 (25.0%)
+++
4 (2.7%)
2 (2.2%)
2 (3.6%)
Immunophenotyping
0.0315d
Type I
27 (18.5%)
14 (15.6%)
13 (23.2%)
Type II
71 (48.6%)
44 (48.9%)
27 (48.2%)
Type III
35 (17.9%)
25 (27.8%)
10 (17.9%)
Type IV
13 (8.9%)
7 (7.8%)
6 (10.7%)
Histologic structure
0.452c
Squamous cell carcinoma
41 (28.1%)
22 (24.4%)
19 (33.9%)
Adenocarcinoma
100 (68.5%)
65 (72.2%)
35 (62.5%)
Other NSCLC
5 (3.4%)
3 (3.3%)
2 (3.6%)
T stage
0.002d
T1
92 (63.0%)
67 (74.4%)
25 (44.6%)
T2
44 (30.1%)
17 (18.9%)
27 (48.2%)
T3
5 (3.4%)
3 (3.3%)
2 (3.6%)
T4
5 (3.4%)
3 (3.3%)
2 (3.6%)
N status
0.0094d
IA
68 (46.6%)
55 (61.1%)
13 (23.2%)
IB
11 (7.5%)
4 (4.4%)
7 (12.5%)
IIA
6 (4.1%)
3 (3.3%)
3 (5.4%)
IIB
34 (23.3%)
19 (21.1%)
15 (26.8%)
IIIA
25 (17.1%)
9 (10.0%)
16 (28.6%)
IIIB
2 (1.4%)
0 (0.0%)
2 (3.6%)
Microvascular invasion
37 (25.3%)
17 (18.9%)
20 (35.7%)
0.023∗b
Perineural invasion
11 (7.5%)
5 (5.6%)
6 (10.7%)
0.409b
Segment resection residue
5 (3.4%)
4 (4.4%)
1 (1.8%)
0.696c
Visceral pleural invasion
36 (24.7%)
21 (23.3%)
15 (26.8%)
0.638b
Bronchial invasion
18 (12.3%)
9 (10.0%)
9 (16.1%)
0.278b
Surgical method
0.738c
Lunglobectomy
112 (76.7%)
71 (78.9%)
41 (73.2%)
Pneumonectomy
7 (4.8%)
3 (3.3%)
4 (7.1%)
Pulmonary wedge resection
15 (10.3%)
9 (10.0%)
6 (10.7%)
Pulmonary sleeve lobectomy
CT features
Spicule sign
102 (69.9%)
58 (64.4%)
44 (78.6%)
0.070b
Lobulation sign
132 (90.4%)
82 (91.1%)
50 (89.3%)
0.716b
Spinous protuberant sign
26 (17.8%)
14 (15.6%)
12 (21.4%)
0.367b
Vascular-bronchial convergent sign
28 (19.2%)
15 (16.7%)
13 (23.2%)
0.329b
Pleural indentation sign
91 (62.3%)
55 (61.1%)
36 (64.3%)
0.700b
Pure ground-glass opacity
12 (8.2%)
12 (13.3%)
0 (0%)
0.011c
Solid opacity
110 (75.3%)
58 (64.4%)
52 (92.9%)
0.000b
Part-solid ground-glass
27 (18.5%)
23 (25.6%)
4 (7.1%)
0.005c
Cavitation
10 (6.8%)
3 (3.3%)
7 (12.5%)
0.073c
Vacuole sign
23 (15.8%)
18 (20.0%)
5 (8.9%)
0.074b
Necrosis
1 (0.7%)
0 (0.0%)
1 (1.8%)
0.810c
Calcification
12 (8.2%)
6 (6.7%)
6 (10.7%)
0.578b
aIndependent samples t-test, bchi-square test, ccorrected chi-square test, and dMann–Whitney U test.
